European Medicines Agency (EMA) has recommended a marketing authorisation in the European Union for Beyfortus (nirsevimab) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in newborn babies and infants during their first RSV season.
RSV can be serious, especially in infants. It is the most common cause of lower respiratory tract infections, such as bronchiolitis (inflammation of the small airways in the lungs) and pneumonia (infection of the lungs) that may lead to hospitalisation or even death in newborn babies and young infants.
FVR – Finnish Vaccine Research has participated in several research studies on RSV prevention, both on infants and the elderly.
Read the original news release, as published on September 16, 2022 by EMA.